Sugie T, et al. - Adjuvant bisphosphonates lead to better prognosis in postmenopausal breast cancer. However, the association between clinical outcomes and immune modulation by them is still unclear. In this current investigation, it was demonstrated that neoadjuvant letrozole (LET) with zoledronic acid, when given to postmenopausal women with early-stage breast cancer, could not achieve overall effect for local tumor response. However, the treatment including zoledronic acid would benefit patients with a low frequency of γδ T cells.